[Ischemic heart disease and prostanoids: pathogenesis and its implications for treatment].
Aoyama
T
T
Department of Internal Medicine, Kyoto University.
Yui
Y
Y
Hattori
R
R
Kawai
C
C
D001095:Arachidonic Acids / Q000378:metabolism / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D003329:Coronary Vasospasm / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors; D011464:Epoprostenol / Q000502:physiology*; D006801:Humans; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D013928:Thromboxane A2; D011464:Epoprostenol; D001241:Aspirin